Stoke Therapeutics (STOK) Net Cash Flow Growth (5y) (2023 - 2026)
Stoke Therapeutics (STOK) Net Cash Flow Growth (5y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn |
| 10 | Stoke Therapeutics | 1.86 Bn | 1.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.94% |
| Dec 31, 2025 | -61.36% |
| Sep 30, 2025 | -11.64% |
| Jun 30, 2025 | -79.29% |
| Mar 31, 2025 | 72.17% |
| Dec 31, 2024 | -15.57% |
| Sep 30, 2024 | -35.17% |
| Jun 30, 2024 | -36.47% |
| Mar 31, 2024 | -13.96% |
| Dec 31, 2023 | -55.73% |
| Sep 30, 2023 | -17.21% |